The Latest Breaking News from FDA

A federal judge is poised to restrict mifepristone – even though the drug has been safely and effectively used in the US for more than 20 years

"This type of activity would fundamentally de-stabilize the FDA regulatory system," a legal expert said.

WASHINGTON — A federal district judge heard oral arguments Wednesday in a controversial case that could decide the fate of the Food and Drug Administration’s approval of the abortion drug mifepristone — a decision that would have broad ramifications nationwide.

The case examines whether the FDA erred in its approval of a drug commonly used for both abortions and miscarriage management.

Nature, last month (paywall): The US Food and Drug Administration (FDA) will soon require [based on new federal legislation] researchers and companies seeking approval for late-stage clinical trials to submit a plan for ensuring diversity among trial participants…. The diversity requirement arrives in the wake of a 2022 report from…

A federal judge has heard arguments in a lawsuit that poses a threat to the nationwide availability of a popular abortion medication

Tracy Droz Tragos’ documentary Plan C, now screening at SXSW, follows the ongoing fight to expand access to abortion medication.

U.S. District Judge Matthew Kacsmaryk said he would rule “as soon as possible” on the request for a preliminary injunction that would move mifepristone, a common abortion-inducing drug, off the market.

A mouse study looked at how high doses of Splenda in mice affected their T cell activation, which could implicate the sweetener's use in autoimmune disorder treatment.

Critics say governments are outsourcing their own knowledge and activities to consulting firms, yet these firms aren't held to the same standards as the public sector.

Anti-abortion groups are pushing to revoke or suspend approval of pill used in more than half of all US abortions.